Tuesday, November 17, 2009

Sinovac's PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population

Sinovac Biotech Ltd., a leading developer and provider of vaccines in China, announced today that it received a revised production license from State Food and Drug Administration for Panflu.1, the Company's H1N1 vaccine. The population has been expanded to include people over 60 years old. The shelf life for PANFLU.1 was extended to one year from six months.

The details can be read here.

No comments: